Drug intelligence / Profile preview

PRO-155

Development stage: Phase 4
Modality: Small Molecules
Administration: Ophthalmic

Overview

PRO-155 is a code name for an ophthalmic solution containing bromfenac 0.09%. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) primarily used to treat ocular inflammation and pain. It functions by inhibiting cyclooxygenase (COX) enzymes, particularly COX-2, which are crucial for the synthesis of prostaglandins. By reducing prostaglandin production, PRO-155 helps alleviate inflammation and pain in the eye. It has been investigated in clinical trials for conditions such as pterygium, ocular inflammation, post-surgical inflammation, and inflammation and pain following phacoemulsification (cataract surgery).

Brand names: ZebestenZebesten ofteno
Other names: bromfenac 0.09% ophthalmic solutionbromfenac ophthalmic solution

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on PRO-155.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-155.

Explore the full profile